| The ABCs of hedge funds: Alphas, betas, and costs RG Ibbotson, P Chen, KX Zhu Financial Analysts Journal 67 (1), 15-25, 2011 | 171 | 2011 |
| Human capital, asset allocation, and life insurance P Chen, RG Ibbotson, MA Milevsky, KX Zhu Financial Analysts Journal 62 (1), 97-109, 2006 | 144 | 2006 |
| Information shocks and short-term market underreaction GJ Jiang, KX Zhu Journal of Financial Economics 124 (1), 43-64, 2017 | 130 | 2017 |
| Lifetime financial advice: human capital, asset allocation, and insurance RG Ibbotson, MA Milevsky, P Chen, K Zhu PRIVATE WEALTH, 23, 2007 | 106 | 2007 |
| Total attention: The effect of macroeconomic news on market reaction to earnings news LH Chen, GJ Jiang, KX Zhu Journal of Banking & Finance 97, 142-156, 2018 | 44 | 2018 |
| Phase 1 study of C-CAR088, a novel humanized anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma X Qu, G An, W Sui, T Wang, X Zhang, J Yang, Y Zhang, L Zhang, D Zhu, ... Journal for immunotherapy of cancer 10 (9), 2022 | 28 | 2022 |
| Dollar-cost averaging, asset allocation, and lump sum investing K Panyagometh, KX Zhu The Journal of Wealth Management 18 (4), 75, 2016 | 17 | 2016 |
| Lifetime financial advice: Human capital RG Ibbotson, MA Milevsky, P Chen, K Zhu Asset Allocation and Insurance, CFA Institute, 2007 | 16 | 2007 |
| Generalized Sharpe ratios: performance measures focusing on downside risk GJ Jiang, KX Zhu International Research Journal of Finance and Economics 30, 132-153, 2009 | 12 | 2009 |
| C-CAR039, a Novel Anti-CD20/CD19 bi-specific CAR T-Cell therapy shows deep and durable clinical benefits in patients with relapsed or refractory (r/r) B-Cell Non-hodgkin … P Li, WJ Yu, L Zhou, M Yang, S Ye, J Zhu, J Huang, Y Zhang, L Li, J Zhao, ... Blood 142, 1025, 2023 | 11 | 2023 |
| Audit market concentration, auditor’s reputation as global and country level market leader, and investor perceived audit quality S Fung, FA Gul, KK Raman, K Zhu Working paper. Hong Kong Polytechnic University, 2012 | 10 | 2012 |
| The a, b, cs of hedge funds: Alphas, betas RG Ibbotson, P Chen, KX Zhu and costs, Working paper, Yale School of Management, 2006 | 10 | 2006 |
| Managed futures and asset allocation P Chen, C O’Neill, K Zhu Ibbotson Associates, February, 2005 | 10 | 2005 |
| Fund of funds, portable alpha, and portfolio optimization P Chen, GJ Jiang, KX Zhu The Journal of Portfolio Management 35 (3), 79-92, 2009 | 9 | 2009 |
| Momentum strategies for style and sector indexes LH Chen, GJ Jiang, KX Zhu Journal of Investment Strategies 1 (3), 67-89, 2012 | 8 | 2012 |
| Do mutual funds trade on earnings news? The information content of large active trades LH Chen, W Huang, GJ Jiang, KX Zhu Journal of Accounting, Auditing & Finance 39 (3), 807-829, 2024 | 5 | 2024 |
| Updated phase 1 results of C-CAR088, an anti-BCMA CAR T-cell therapy in relapsed or refractory multiple myeloma X Qu, G An, W Sui, T Wang, X Zhang, J Yang, Y Zhang, L Zhang, J Zhu, ... Blood 138 (Supplement 1), 1830-1830, 2021 | 5 | 2021 |
| Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). A Liang, L Zhou, P Li, W Yu, M Yang, Y Xu, S Ye, J Zhu, J Huang, Y Zhang, ... Journal of Clinical Oncology 39 (15_suppl), 2507-2507, 2021 | 5 | 2021 |
| Information uncertainty of fiscal year end quarter earnings LH Chen, GJ Jiang, KX Zhu Review of Accounting and Finance 21 (2), 83-108, 2022 | 4 | 2022 |
| Breast Implant–Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Are You Covered? M Ha, LM Ngaage, K Zhu, N Hricz, S Slezak, YM Rasko Aesthetic surgery journal 41 (12), NP1943-NP1949, 2021 | 4 | 2021 |
